The complexity of health and disease cannot be captured by a singular diagnostic test and therefore can’t be expected to deliver true impact. Attempting to create a paradigm shift in diagnostics development by making them 10x more effective, faster and impactful is London-based early-stage biotech company Sanome.
The health startup has raised £2 million as its first round of funding from a number of leading UK and European health tech specialist investors. The round was led by Heal Capital, with participation from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind and a number of high-profile angels, including David Cleevely and Pam Garside.